Boehringer Ingelheim's Survodutide Shows Strong Weight‑Loss Results but Raises Tolerability Concerns

Phase III data from the Synchronize‑1 trial of Boehringer Ingelheim’s investigational dual GLP‑1/glucagon agonist survodutide demonstrated up to 16.6 % body‑weight loss after 76 weeks, with visceral‑fat reductions of up to 34 % and liver‑fat reductions of up to 63 % versus placebo. A separate MASLD trial showed 68‑84 % of survodutide‑treated participants achieved at least a 30 % reduction in liver fat, compared with roughly 24 % on placebo.

Gastro‑intestinal adverse events were common; 19‑25 % of patients discontinued the drug because of nausea, vomiting, diarrhoea or constipation, versus 2.9 % on placebo. Boehringer executives said the tolerability profile is consistent with the drug class and noted that lean‑mass loss was limited to about 10.8 % of total tissue loss. The efficacy results are broadly comparable to Novo Nordick’s semaglutide and below those reported for Eli Lilly’s tirzepatide, prompting a sell‑off in the shares of licence‑holder Zealand Pharma.

Researchers highlighted the potential to address obesity‑related liver disease in addition to weight loss, positioning survodutide as a possible differentiated therapy in a crowded metabolic‑health market.